ClinicalTrials.gg
CompletedNCT02197728Updated Feb 22, 2019

Comparing Two Devices of Uterine Manipulation and Vaginal Fornix Delineation at Total Laparoscopic Hysterectomy

An interventional study of Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy in Laparoscopic Hysterectomy for Benign Conditions, sponsored by Unity Health Toronto. Completed at 1 site in Canada. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-22.

Sponsored by Unity Health Toronto · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

We hypothesize, that the use of the Hohl manipulator® at total laparoscopic hysterectomy reduces operative time (from skin incision to detachment of the uterus) and lateral termal damage of the vaginal wall during colpotomy due to the following reasons: (1) Uterine manipulation is better with the Hohl manipulator®, thereby facilitating dissection during all aspects of the surgery, (2) more tension can be applied on the vagina during colpotomy, thereby hastening electrosurgical transection, reducing activation time and reduce lateral thermal damage and (3) tension on the vagina can be applied until the colpotomy is finished, due to the tight connection between the Hohl manipulator® and the cervix of the uterus, which also affects speed of transection, electrosurgical device activation time and lateral thermal damage.

02

Conditions studied

  • Laparoscopic Hysterectomy for Benign Conditions

Keywords

  • hysterectomy, uterine manipulator, thermal damage, laparoscopy, colpotomy
03

In context

Lead sponsor

Unity Health Toronto is the lead sponsor of 444 studies on the registry; 80 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All women aged over 18 years, scheduled for a laparoscopic hysterectomy for a benign disorder will be asked to participate and included after written informed consent.

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • malignancy
  • if uterine size exceeds 20 weeks of gestation
  • or if the uterus could be removed by a vaginal approach
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
91 participants (actual)

Study arms

  • Active comparator
    Hohl uterine manipulator ®

    Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®

    Device: Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy

  • Active comparator
    Colpo-Probe™ Vaginal Fornix Delineator

    Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator

    Device: Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy

Interventions

  • DeviceUse of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy
06

What researchers measure

Primary outcomes

  1. Detachment of the uterus

    Operative time from skin incision to detachment of uterus. Times are routinely collected by operating room nursing staff.

    Time frame: 45 minutes to 3 hours

  2. Thermal Damage

    Lateral thermal damage to the vagina will be measured on the specimen (in mm) at the time of pathologic evaluation.

    Time frame: 2 weeks post surgery

  3. Colpotomy

    Time from first monopolar energy activation to completion of colpotomy. Operative times are routinely collected by operating room nursing staff.

    Time frame: 3 minutes to 20 minutes

Secondary outcomes

  1. Blood Loss

    Total amount of blood lost throughout surgery. Measured in cc.

    Time frame: 45 minutes to 3 hours

  2. Pain

    Amount of post operative pain measured using a pain sensitivity scale.

    Time frame: 24h post surgery

  3. Manipulator Installment

    Time frame: intraoperative

07

Study locations

1 site
  • St. Michael´s Hospital
    Toronto, Ontario M5B 1W8, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2014
First posted
Jul 23, 2014
Start
Feb 2014
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Feb 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02197728
Responsible party
Sponsor
First posted
Jul 23, 2014
Start date
Feb 2014
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Feb 22, 2019

Study contacts

Guylaine Lefebvre, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion